🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

41 results for “PUMA” Clear

  1. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 3 small molecule active

    8 trials

  2. neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2+ Metastatic Breast Cancer (MBC)

    phase 3 small molecule completed

    1 trial

  3. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Hormone Receptor Positive HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  4. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer ( SCLC )

    phase 2 small molecule active

    1 trial

  6. Capecitabine

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Fulvestrant STADA 250 mg injekcinis tirpalas užpildytame švirkšte, Alisertib Enteric-Coated Tablets, Exemestane SanoSwiss 25 mg plėvele dengtos tabletės, Anastrozole Accord 1 mg plėvele dengtos tabletės, Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės, Tamoxifen EBEWE 20 mg tabletės

    PUMA BIOTECHNOLOGY, INC.

    Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

    phase 2 small molecule active

    1 trial

  8. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Advanced Breast Cancer

    phase 2 small molecule completed

    2 trials

  9. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  10. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  11. NERATINIB

    PUMA BIOTECHNOLOGY, INC.

    Stage IV (Metastatic) Breast Cancer

    phase 2 small molecule terminated

    1 trial

  12. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial

  13. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  14. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Anatomic Stage I Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early-stage Breast Cancer

    phase 2 small molecule active

    1 trial

  16. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early Stage HER2+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  17. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    GastroEsophageal Cancer

    phase 2 small molecule active

    1 trial

  18. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2 Amplified Breast Cancer

    phase 2 small molecule completed

    1 trial

  19. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  20. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Prostate Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  21. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  22. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

    phase 2 small molecule terminated

    1 trial

  23. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  24. PIRTOBRUTINIB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources